Milestone Pharma (MIST) Q4 2025 earnings review
FDA Approval Transforms Milestone into a Commercial Entity, Cash Burn Accelerates
Milestone Pharmaceuticals has officially transitioned to a commercial-stage company following the FDA approval of its CARDAMYST nasal spray in December 2025. Revenue saw a reversing trend, jumping from zero to $1.5M in Q4 driven entirely by a milestone payment from Corxel Pharmaceuticals. However, the bottom line reflects the steep cost of commercialization: Q4 net loss expanded to $17.4M, driven by an accelerating commercial spend as the company deployed a 60-person sales force. Crucially, a $75M milestone payment from RTW Investments and $19M in recent equity financing fortified the balance sheet, providing a $200M pro forma cash position that extends the operational runway into late 2027.
🐂 Bull Case
CARDAMYST is the first new treatment option for PSVT in 30 years, allowing more than two million patients to self-administer rapid-acting therapy outside of emergency departments.
The $75M royalty payment triggered by FDA approval, combined with recent equity raises, brings pro forma cash to $200M—securing the company's runway into late 2027 without immediate dilution risk.
🐻 Bear Case
Early prescription fills are heavily reliant on company-sponsored reimbursement support ahead of actual payer coverage, which will likely severely pressure early gross-to-net margins.
Full-year commercial expenses accelerated from $11.0M in FY24 to $28.3M in FY25. If CARDAMYST adoption is slower than expected, this fixed cost base will accelerate cash burn.
⚖️ Verdict: ⚪
Neutral. The FDA approval and the resulting $200M cash infusion successfully de-risked the near-term balance sheet. However, the transition from clinical-stage to commercial-stage is historically treacherous, and accelerating expenses mean management must execute flawlessly on the CARDAMYST launch to justify the current valuation.
Key Themes
CARDAMYST Launch Execution
The commercial rollout is officially underway. CARDAMYST hit retail pharmacies in late January 2026, and a 60-person national sales force was fully deployed by mid-February targeting cardiologists and electrophysiologists. Management noted that early prescription fills indicate strong underlying demand and successful targeting by the sales force.
Accelerating Commercial Expenditures
The cost of building a commercial infrastructure is becoming evident in the P&L. Commercial expense for Q4 was $8.2M (nearly double the $4.4M in 24Q4), bringing FY25 commercial spend to $28.3M. This accelerating trajectory is expected to continue as promotional activities scale up throughout 2026.
AFib-RVR Clinical Expansion
With the PSVT approval secured, the company is reviving its clinical pipeline. Management confirmed plans to initiate a Phase 3 registrational program for Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR). By utilizing the supplemental New Drug Application (sNDA) pathway, Milestone hopes to leverage the existing PSVT safety data to shorten the development timeline.
Payer Coverage and Reimbursement Lag
While early prescriptions are being filled, the company admitted these rely heavily on internal 'investments in reimbursement support ahead of coverage by payers.' This indicates that actual recognized revenue might trail prescription volume until broad formulary access is established, a common but expensive hurdle in the first 6-12 months of a new drug launch.
Clinical Innovation: Minimal Blood Pressure Effects
A crucial selling point for self-administered cardiac medication is safety. At the upcoming ACC Scientific Session, Milestone will present data showing minimal blood pressure reduction and rare symptoms of hypotension from CARDAMYST. This data is vital for driving physician confidence in allowing patients to use the spray without direct medical supervision.
Convertible Debt Overhang
Despite the healthy pro forma cash balance, the company continues to carry $57.2M in senior secured convertible notes as of year-end (up from $53.4M in 2024). While not an immediate liquidity threat, this debt creates an overhang that will need to be serviced or converted down the road.
Other KPIs
Accelerating liquidity. The year-end cash balance was $106.0M, but a $75M payment from RTW in January 2026 (triggered by the FDA approval) plus $19M from recent ATM and warrant exercises fundamentally transformed the balance sheet. This capital removes the immediate necessity for dilutive public offerings during the early launch phase.
Accelerating from $14.4M in FY24. The increase was driven by higher consulting and outside service costs, likely associated with finalizing the regulatory package for CARDAMYST and preparing for the upcoming AFib-RVR Phase 3 trials.
Stable compared to $16.7M in the prior year. Management effectively controlled administrative overhead even as commercial expenditures spiked, showing disciplined capital allocation in non-revenue generating departments.
Guidance
Management explicitly stated that the $200M pro forma cash balance provides strong operating runway into late 2027. This is a highly positive signal, giving the company approximately 21-24 months of runway to secure broad payer coverage and ramp up CARDAMYST sales without requiring emergency capital.
The European Medicines Agency has accepted the Marketing Authorization Application for etripamil. If approved, this will unlock a secondary geographic revenue stream for the company.
Key Questions
Gross-to-Net Dynamics
With the current reliance on company-sponsored reimbursement support programs, what are the internal expectations for gross-to-net margin during the first 12 months of the CARDAMYST launch?
Payer Coverage Timeline
When does management expect to secure broad Tier 2 or Tier 3 formulary access with major commercial payers and Medicare Part D?
AFib-RVR Trial Capital Requirements
Does the 'late 2027' cash runway guidance fully bake in the R&D costs associated with conducting the upcoming AFib-RVR Phase 3 registrational program?
Prescription Metric Disclosures
Management noted future quarters will report total prescriptions and unique prescribers. Will the company also break out the refill rate versus new patient starts to help analysts track true recurring demand?